| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 147, 1278-1288, Copyright © 1995 by American Society for Investigative Pathology
REGULAR ARTICLES |
A Almenar-Queralt, A Duperray, LA Miles, J Felez and DC Altieri
Department of Cell Biology, Scripps Research Institute, La Jolla, California, USA.
Leukocyte-endothelium interactions and general inflammatory responses are contributed by the regulated expression of intercellular adhesion molecule-1 (ICAM-1) on endothelium. It is now shown by confocal fluorescence microscopy and immunogold transmission electron microscopy that ICAM-1 was exclusively localized on the apical (luminal) membrane of cytokine-activated human umbilical vein endothelial cells. In contrast, other cell adhesion-promoting molecules, including beta 1 integrins, were expressed exclusively on the basolateral endothelial cell membrane, under the same experimental conditions. Kinetic binding studies of a 125I-labeled monoclonal antibody to ICAM-1 revealed that approximately 8% of membrane ICAM-1 on cytokine-activated endothelium was internalized in both coated and non-coated vesicles at 37 degrees C, with a t1/2 of approximately 18 min and a rate of approximately 3200 molecules/minute. This internalization pathway was directly dependent upon the level of ICAM-1 expression on the cell surface. Genetically engineered ICAM-1 transfectants, expressing a 10-fold higher receptor density than activated endothelium, internalized approximately 18% of membrane ICAM-1 at a rate of 75,000 molecules/minute with a t1/2 of approximately 22 min. These findings suggest that a combined pathway of polarized membrane topography and receptor trafficking may regulate ICAM-1-dependent adhesion at the site of vascular injury and endothelial cell activation.
This article has been cited by other articles:
![]() |
S. Muro, C. Gajewski, M. Koval, and V. R. Muzykantov ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs Blood, January 15, 2005; 105(2): 650 - 658. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Murciano, S. Muro, L. Koniaris, M. Christofidou-Solomidou, D. W. Harshaw, S. M. Albelda, D. N. Granger, D. B. Cines, and V. R. Muzykantov ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface Blood, May 15, 2003; 101(10): 3977 - 3984. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Sans, E. Delachanal, and A. Duperray Analysis of the Roles of ICAM-1 in Neutrophil Transmigration Using a Reconstituted Mammalian Cell Expression Model: Implication of ICAM-1 Cytoplasmic Domain and Rho-Dependent Signaling Pathway J. Immunol., January 1, 2001; 166(1): 544 - 551. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Jaakkola, T. Nikula, R. Holopainen, T. Vahasilta, M.-T. Matikainen, M.-L. Laukkanen, R. Huupponen, L. Halkola, L. Nieminen, J. Hiltunen, et al. In Vivo Detection of Vascular Adhesion Protein-1 in Experimental Inflammation Am. J. Pathol., August 1, 2000; 157(2): 463 - 471. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. R. Muzykantov, M. Christofidou-Solomidou, I. Balyasnikova, D. W. Harshaw, L. Schultz, A. B. Fisher, and S. M. Albelda Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): A strategy for vascular immunotargeting of drugs PNAS, March 2, 1999; 96(5): 2379 - 2384. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. N. Atochina, I. V. Balyasnikova, S. M. Danilov, D. N. Granger, A. B. Fisher, and V. R. Muzykantov Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress Am J Physiol Lung Cell Mol Physiol, October 1, 1998; 275(4): L806 - L817. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Schober, P. Kronenberger, E. Prchla, D. Blaas, and R. Fuchs Major and Minor Receptor Group Human Rhinoviruses Penetrate from Endosomes by Different Mechanisms J. Virol., February 1, 1998; 72(2): 1354 - 1364. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |